Northwire Canada EditionThursday, July 23, 2026
Sign inSubscribe
Northwire
⌕
VZZ 0.180 +2.9% BMR 0.145 +3.6% NVO 0.055 −8.3% PMET 4.47 +2.0% CTG 0.125 +13.6% AVU 0.040 +0.0% SGML 14.32 −3.1% WRLG 0.720 +1.4% CAN 0.065 +8.3% ABRA 15.63 +1.6% LSTR 0.060 +0.0% OLA 13.10 +2.5% EQX 13.15 +2.7% SRA 0.780 +0.0% UTWO 0.390 −13.3% IVN 10.64 −1.2% VZZ 0.180 +2.9% BMR 0.145 +3.6% NVO 0.055 −8.3% PMET 4.47 +2.0% CTG 0.125 +13.6% AVU 0.040 +0.0% SGML 14.32 −3.1% WRLG 0.720 +1.4% CAN 0.065 +8.3% ABRA 15.63 +1.6% LSTR 0.060 +0.0% OLA 13.10 +2.5% EQX 13.15 +2.7% SRA 0.780 +0.0% UTWO 0.390 −13.3% IVN 10.64 −1.2%
Financings

Briacell receives $2.05M Bria-PROS+ research grant

By The Northwire Desk — AI Analysis Aug 25, 2025 · 17:38 BCT · 10.41 Briacell Therapeutics Corp
BCT · Price

Executive Summary

  • Briacell Therapeutics Corp. has been awarded a non-dilutive research grant of $2,054,651 from the National Cancer Institute (NCI).
  • The funding is designated to advance Bria-PROS+, a next-generation personalized off-the-shelf immunotherapy for prostate cancer.
  • Proceeds will be used to complete the manufacturing of Bria-PROS+ and finance an upcoming Phase 1/2a clinical trial in patients with metastatic prostate cancer.

Key Details

  • Grant Amount: $2,054,651.
  • Funding Source: National Cancer Institute (NCI), the U.S. federal government's principal agency for cancer research and training.
  • Grant Type: Non-dilutive research grant.
  • Project Title: "Phase 1/2a clinical trial to investigate Bria-PROS+ in patients with metastatic prostate cancer."
  • Use of Proceeds:
    • Complete manufacturing of Bria-PROS+.
    • Finance the coming Phase 1/2a study in patients with advanced prostate cancer.
  • Product: Bria-PROS+, described as a next-generation personalized off-the-shelf immunotherapy.
  • Platform: The Bria-OTS+ platform, designed to overcome the complexity, cost, and delays of traditional personalized cancer treatments.
  • Key Personnel:
    • Dr. William Oh, MD (Director of Precision Medicine, Yale Cancer Center; Principal Investigator on the Phase 1/2a study).
    • Dr. William V. Williams (President and CEO, Briacell).
    • Miguel Lopez-Lago, PhD (Chief Scientific Officer, Briacell).

Notable Quotes

  • "Despite recent advances in the management of metastatic hormone-sensitive prostate cancer, most patients will progress with significant pain and suffering and limited treatment options... We are grateful to the NCI for recognizing the urgency for this unmet medical need and supporting Briacell's breakthrough immunotherapy." — Dr. William Oh, MD
  • "This prestigious award will help expedite the clinical development of Bria-PROS+ and is significant validation of our next-generation novel personalized immunotherapy approach." — Dr. William V. Williams
  • "The Bria-OTS+ platform was designed to overcome the complexity, cost and delays of traditional personalized cancer treatments... We believe it will constitute a significant advancement in personalized cancer care." — Miguel Lopez-Lago, PhD
Read the original news release →

More from Briacell Therapeutics Corp

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other